Cargando…
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
[Image: see text] The anaplastic lymphoma kinase (ALK) is abnormally expressed and hyperactivated in a number of tumors and represents an ideal therapeutic target. Despite excellent clinical responses to ALK inhibition, drug resistance still represents an issue and novel compounds that overcome drug...
Autores principales: | Mologni, Luca, Tardy, Sébastien, Zambon, Alfonso, Orsato, Alexandre, Bisson, William H., Ceccon, Monica, Viltadi, Michela, D’Attoma, Joseph, Pannilunghi, Sara, Vece, Vito, Bertho, Jerome, Goekjian, Peter, Scapozza, Leonardo, Gambacorti-Passerini, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134258/ https://www.ncbi.nlm.nih.gov/pubmed/35647450 http://dx.doi.org/10.1021/acsomega.2c00507 |
Ejemplares similares
-
Correction to “Discovery of Novel α-Carboline
Inhibitors of the Anaplastic Lymphoma Kinase”
por: Mologni, Luca, et al.
Publicado: (2022) -
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015) -
Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012) -
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015) -
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
por: Cecchini, Carlotta, et al.
Publicado: (2021)